Having reached a landmark agreement with Gilead Sciences Inc., EVA Pharma is proud to announce that it is a licensed manufacturer for the antiviral treatment “Remdesivir – EVA Pharma” under voluntary license.
Remdesivir had been the first medication to be approved by the U.S. FDA for Emergency Use Authorization (EUA) for the treatment of adult and pediatric patients with suspected or laboratory-confirmed SARS-CoV-2 infection and severe COVID-19. Also, it became the first medicine against COVID-19 to be recommended for authorization in the EU by the EMA.
EVA Pharma is gladly inviting you to be our partner in the battle against COVID-19, as we are opening doors for exporting Remdesivir-EVA Pharma to 126 countries.
For more info please contact us